Pacira BioSciences (PCRX) Net Cash Flow (2010 - 2026)

Pacira BioSciences' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$14.3 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 308.85% year-over-year to -$14.3 million in Q1 2026; TTM through Mar 2026 was -$139.3 million, a 239.88% decrease from a year earlier, with the FY2025 full-year figure at -$118.2 million, down 195.69% from the prior year.
• Net Cash Flow slipped to -$14.3 million in Q1 2026 per PCRX's latest filing, from $11.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $63.0 million in Q2 2024 and bottomed at -$358.8 million in Q1 2022.
• The 5-year median for Net Cash Flow is $6.8 million (2025), against an average of -$26.0 million.
• Across the five-year window, Net Cash Flow soared 1125.15% in 2023 and sank 13965.07% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$5.3 million in 2022, then surged by 1125.15% to $54.2 million in 2023, then slumped by 43.13% to $30.8 million in 2024, then sank by 63.1% to $11.4 million in 2025, then plunged by 225.57% to -$14.3 million in 2026.
• Per Business Quant, the three latest PCRX Net Cash Flow figures stand at -$14.3 million (Q1 2026), $11.4 million (Q4 2025), and -$153.0 million (Q3 2025).